Kyverna Therapeutics, Inc. Other Non-Current Liabilities
Kyverna Therapeutics, Inc. (KYTX) had Other Non-Current Liabilities of $296.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2024-11-13
- 2024-09-30: Other Liabilities, Noncurrent $296.00K.
| Period end | Other Liabilities, Noncurrent |
|---|---|
| 2024-09-30 | $296.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |